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Purpose: There are increased levels of nitric oxide (NO) in diabetic retinas. The purpose of this study was to determine
the extent that neuronal nitric oxide synthase (nNOS) contributes to the increased levels of retinal NO in early diabetic
retinopathy by examining the expression and activity of nNOS in retinal neurons after 5 weeks of diabetes.
Methods: Changes in NO levels were measured using NO imaging of retinal neurons in mice with streptozotocin-induced
diabetes for five weeks. NO imaging was compared to nNOS localization using immunocytochemistry, and nNOS message
and protein levels were measured using quantitative real-time PCR and western blots.
Results: There was a close anatomic correlation between the localization of the increased NO production and the nNOS
immunoreactivity in the retinal plexiform layers of diabetic retinas. There was no change in nNOS message, but nNOS
protein was decreased and its subcellular localization was altered. Treatment with insulin or aminoguanidine partially
ameliorated the increase in NO in diabetic retinas.
Conclusions: These results suggest that increased nNOS activity is responsible for the majority of increased NO in retinal
neurons in early diabetic retinopathy. This supports a role for increased nNOS activity in the early neuronal dysfunction
in the diabetic retina.
Diabetic retinopathy (DR) is one of the leading causes of
blindness among working age adults in the developed world
[1]. DR is characterized by both neuronal dysfunction and the
breakdown of the retinal vasculature [2]. Complications in the
vasculature are important for disease progression and are easy
to detect clinically. As a consequence, many studies have
approached DR as being primarily vascular in its etiology.
However, retinal neuron dysfunction occurs early in DR and
may even precede vascular breakdown [3,4].
Evidence of early neuronal dysfunction is demonstrated
as aberrant electroretinogram (ERG) responses before any
visible vascular damage in diabetic rats [4,5] and humans [6,
7]. Shirao and Kawasaki [8] concluded that the oscillatory
potentials (OP) were the first ERG components affected in
diabetes. OP changes are a better predictor of DR in humans
than fundus photography or fluorescein angiograms [9].
Evidence for changes in visual processing has been seen in as
little as two weeks in diabetic rats [10], while discernable
vascular changes have been noted to occur after six months to
one year [11]. Similarly, there is a decrease in color and
contrast sensitivity and aberrant ERGs in diabetic humans
after two years [12-14], while major vascular changes do not
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typically occur until 5–10 years after the onset of diabetes
[3].
Several neurochemical changes have also been
documented early in the diabetic retina. For example, Leith et
al. [15] found increased glial fibrillary acidic protein (GFAP)
in Müller cells along with increased levels of glutamate and
an impaired breakdown of glutamate to glutamine. There is
an increase in retinal neuron apoptosis early in DR, which also
precedes the vascular damage in both rodents and humans
[16,17]. The presynaptic proteins synaptophysin, synapsin 1,
VAMP2, SNAP25, and PSD95 all show decreases after only
one month of diabetes, especially when synaptosomal
fractions are selectively examined [18]. A study by Kern et al.
[19] showed that early vascular damage was prevented in rats
by administering the COX inhibitor, nepafenac, but retinal
ganglion cell apoptosis still occurred, denoting a separation
between vascular and neuronal damage.
Nitric oxide (NO) is an important signaling molecule in
the vertebrate retina found to either be produced by or have
effects in every retinal cell type [20]. There is evidence for
increased NO in both the vitreous and aqueous humors of
patients with DR [21,22]. We have previously shown that
neuronal nitric oxide synthase (nNOS) is the primary source
of neuronal NO and the most abundant form of nitric oxide
synthase (NOS) in retina [23-25]. However, there is little
characterization of nNOS in DR, and the results have been
inconsistent [26,27].
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In this study, we examined changes in NO and nNOS in
the retinas of mice that had streptozotocin-induced diabetes
(STZID) for five weeks. We found no change in nNOS
message levels, but nNOS protein levels decreased and its
subcellular localization was altered in the inner plexiform
layer (IPL). Despite this, total NO levels quantified using the
NO-sensitive dye diamino-5-methylamino-2',7’-
difluorofluorescein diacetate-FM (DAF-FM) increased
significantly. The increased NO production was closely
anatomically correlated with the immunocytochemical
localization of nNOS. The results of this study suggest that
nNOS enzyme activity is upregulated early in DR and is
concomitant with neuronal dysfunction.
METHODS
Unless specified otherwise, all reagents were purchased from
Sigma (St. Louis, MO) or Fisher Scientific (Waltham, MA).
All of the experiments were done in normal room light, with
the exception of the NO imaging, which, for technical reasons,
was done using dark-adapted retinas. All statistical
evaluations were performed using OriginPro 8 software
(OriginLab, North Hampton, MA).
Animals: Adult (between 3 and 5 months of age), male
C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA) and were kept on a standard
12 h:12 h light-dark cycle with free access to food and water.
All animals were treated using protocols approved by the
Boston University Charles River Campus Institutional
Animal Care and Use Committee. Mice were age matched and
made diabetic by an intraperitoneal (IP) injection of 75 mg/kg
streptozotocin (STZ; Alexis Biochemicals, San Diego, CA) in
pH 4.5 citrate buffer; each injection was given after an 8-h
fast, one injection per day for three consecutive days. Control
animals received three IP injections of citrate buffer alone
after an 8 h fast on the same days as the experimental animals.
The animals were allowed to recover for two days before their
blood glucose levels were tested with a FreeStyle FlashTM
blood glucose meter (Therasense, Almeda, CA). Mice were
considered diabetic if their fasting blood glucose level was at
or over 250 mg/dl. Animals that did not become diabetic were
not used for this study. Treatment with insulin,
aminoguanidine (AG), or Nω-nitro-L-arginine methyl ester
(L-NAME) was given to subsets of animals starting one week
after induction of diabetes. Thus, these treatments were given
for a duration of 4 weeks up to the time of sacrifice as follows.
Once a day, 2 U/kg insulin from bovine pancreas (in sterile
saline; Sigma I5500) was administered via IP injection. Also
once a day, NOS inhibitor L-NAME (37.5 mg/kg in sterile 0.1
M pH 7.4 phosphate buffer, PB) was administered by IP.
Every day, 1 g/l AG, an inhibitor of both NOS and advanced
glycation end product (AGE) formation, was administered to
animals in their drinking water, which was changed daily.
Animal weight and fasting blood glucose levels were recorded
at the beginning and end of each experimental cycle. Final
blood glucose levels and bodyweights were compared
between each group using ANOVA. Post hoc analysis was
performed using Tukey’s test. A p<0.05 was considered
significant. Animals were euthanized in each experiment by
exposing them to IsoFlow™ Isoflurane gas (Abbott
Laboratories) until they were deeply anesthetized, and then
they were immediately decapitated.
Protein extraction and western blotting: Following
sacrifice, the eyes were rapidly removed and placed into
balanced salt solution (BSS; 137 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 15 mM D-glucose, 1 mM MgSO4, 1 mM Na2HPO4, and
10mM HEPES, pH 7.4) and the retinas were then surgically
isolated from the eyes. Specimens in solution were
immediately placed into 1.5 ml centrifuge tubes, set on dry
ice. Six retinas (three animals) were pooled together to ensure
an adequate amount of protein for detection by western
blotting. The retinas were then suspended in 200 μl of
homogenization buffer containing 20 mM Tris-HCl, 0.05%
SDS, and 1X Complete Mini Protease Inhibitor Cocktail with
EDTA (Roche Applied Science, Indianapolis, IN) before
being ultrasonically homogenized. The protein concentration
in each sample was determined using the Bradford method. In
each lane, 100 μg protein was loaded onto 8% SDS PAGE
gels and transferred onto 0.4 μm Immobilon™ PVDF
membranes (Millipore, Billerica, MA). A rapid detection
method was used, whereby the blocking step was omitted
[28]. The primary antiserum was a rabbit anti-nNOS (sc648;
Santa Cruz Biotechnology, Santa Cruz, CA) that was diluted
1:5,000 in 2% BSA in Tris buffered saline w/ 0.25%
Tween-20 (TBST). The secondary antibody was a horseradish
peroxidase-conjugated goat polyclonal antiserum raised
against rabbit IgG (Molecular Probes, Invitrogen, Carlsbad,
CA) at a dilution of 1:100,000. The blots were then treated
with Immobilon™ HRP substrate (Millipore) and exposed to
blue X-ray film (F-BX57; Phenix, Asheville, NC). To confirm
equal lane loading, we stripped the blots and reprobed them
with mouse anti-β-tubulin. The β-tubulin monoclonal
antibody used was developed by Dr. Willi Hafler and was
obtained from the Developmental Studies Hybridoma Bank.
This antibody was developed under the auspices of the
NICHD and is maintained by The University of Iowa
(Department of Biology, Iowa City, IA). Quantitative analysis
was performed using Image J image analysis software (Wayne
Rasband, National Institute of Mental Health, Bethesda, MD).
The difference in protein levels was evaluated using the paired
Student’s t-test. A p<0.05 was considered significant.
Immunocytochemistry: After euthanasia, the mouse eyes
were rapidly enucleated and placed in ice-cold BSS. The
anterior chamber, lens, and vitreous were then removed and
the resultant eyecups were immediately placed into 4%
paraformaldehyde in PB for 90 min at room temperature.
Next, the eyecups were cryoprotected in 30% sucrose in PB,
embedded and frozen in Optimal Cutting Temperature
embedding media (OCT; Tissue-Tek, Miles, Inc., Elkhard,
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IN), and cut into 14 µm thick cross-sections using a cryostat
and mounted on Superfrost /Plus® slides (Fisher Scientific).
The eyecups from the control and diabetic mice were
embedded into the same block and cryosectioned onto the
same slide to reduce variability when comparing changes in
immunoreactivity. The asymmetry provided by this
embedding method allowed us to clearly distinguish each of
the eyecups in the resultant cryosections. Thus we could
embedded one eye from each of 4 separate mice with different
treatments in the same block.
Immunocytochemistry was performed on the retinal
sections using standard methods as previously described
[25,29] on retinal cross-sections mounted on slides.
Immunochemical procedures were replicated, using at least
three different animals (n=3), where each "n" was the average
of three trials for a given animal compared to the other retinas
on the same slide as described in the previous paragraph. The
primary antiserum used was rabbit anti-nNOS (sc648; Santa
Cruz Biotechnology) at a dilution of 1:1,000 overnight in a
humid chamber at 4 °C. The slides were then washed 3×10
min in 0.1 M PB at room temperature and then incubated for
2 h in an Alexa488-conjugated goat anti-rabbit IgG secondary
antiserum (Molecular Probes, Carlsbad, CA) at a dilution of
1:500. Incubation with the primary antiserum omitted served
as a control for nonspecific secondary antiserum staining.
Slides were washed in 0.1 M PB as before, coverslipped with
glycerol, and the fluorescent signal was visualized using an
Olympus Fluoview™ 300 confocal microscope (Olympus,
Melville, NY). The excitation was done using the 488 nm laser
line from an argon laser and the emission was visualized using
a 510–550 nm bandpass filter. Ten to 14 optical sections were
taken at 1 μm intervals, with the same number of optical
sections always being captured and compared for both the
control and experimental retinas. The laser intensity and all
confocal settings were kept consistent within replicates.
The “z project” function of Image J image analysis
software was used to obtain a single image from a collapsed
confocal optical stack. The images were then converted to
inverted grayscale so that the immunoreactivity would appear
black. Mean intensity values were then recorded for each
treatment and compared to the control retina on the same slide.
These values were averaged together for each animal and
compared to the average control mean using the paired
Student’s t-test. A p<0.05 was considered significant. The
relative intensity of immunoreactivity within each retinal
layer was quantified using Image J to produce a horizontal
line-profile average of the intensity of the immunoreactivity
in the different retinal layers, minimizing the effect of local
regional differences.
RNA isolation and reverse transcription: The retinas
were isolated in BSS as described in the
immunocytochemistry methods section, although all reagents
and materials were kept RNase-free. Total RNA was then
isolated from the retinas using a standard Trizol™ reagent
(Invitrogen, Carlsbad, CA) extraction. To obtain sufficient
amounts of RNA to perform these reactions, we pooled three
animals (six retinas) together for each extraction. The RNA
was then treated with rDNase™ (Ambion, Applied
Biosystems, Austin, TX), following the manufacturer’s
instructions, to remove any DNA contaminants. The RNA
was quantified using a Nanodrop™ spectrophotometer
(ThermoFisher Scientific, Waltham, MA). RNA was then
converted into cDNA using the Verso™ cDNA kit
(ThermoFisher Scientific) and subsequently treated with 2 U
of RNase H™ (ThermoFisher Scientific) at 37 °C for 20 min.
Quantitative real-time PCR analysis: Quantitative real-
time PCR analysis (qPCR) was performed using cDNA
converted from 1 µg of retinal RNA as described in the
previous section, using an ABI PrismTM 7900HT Sequence
Detection System (Applied Biosystems, Carlsbad, CA). We
used a pre-designed TaqMan™ gene expression assay
(Applied Biosystems) for nNOS (assay ID:
Mm00435173_m1). Our normalizing control was an
optimized 18s rRNA primer set that was kindly provided to
us by Dr. Ulla Hansen (Boston University, Boston, MA),
which was designed to work with SYBR Green™ (Applied
Biosystems). All data was obtained in quadruplicate and
analyzed using the Microsoft ExcelTM qGene template [30].
NO imaging: NO imaging was performed as reported
previously [24]. Since DAF-FM is a light sensitive dye, all
aspects of the NO imaging experiments, beginning with the
retinal eyecups, were done in the dark using infrared imaging,
except for the actual final light stimulations. To prepare retinal
slices, we enucleated the eyes and removed the anterior
segment of the eye and lens under dim light. We placed the
eyecups in chilled aerated artificial cerebrospinal fluid
(ACSF, 125 mM NaCl, 26 mM NaHCO3, 3 mM KCl, 1.6 mM
CaCl2, 1.5 mM MgSO4, 1.25 mM NaH2PO4, and 10 mM
glucose) in the dark on ice for 1 h to allow the retinas to recover
and fully dark adapt. The eyecups were then sectioned into
250-µm-thick slices. Loading of the NO-sensitive dye, DAF-
FM (Molecular Probes), was done as previously described
[31]. Briefly, slices were allowed to recover from slicing for
at least 30 min in ACSF at room temperature and then
incubated for 60 min in ACSF containing 10 µM of DAF-FM
at 37 °C. Slices were then washed 3x 15 min with fresh,
aerated ACSF at 37 °C.
Some slices were stimulated for 20 min with a light
emitting diode (660 nm, 3Hz, 20 µW, 25% duty cycle), while
a matched set of slices were kept in the dark for comparison.
Light-stimulated and control sections were then fixed in the
dark for 2 h with 4% paraformaldehyde in PB and then they
were washed 4×15 min in 0.1 M PB at room temperature.
Fluorescent images of the retinal slices were acquired using a
FluoviewTM 300 confocal microscope (Olympus Corporation)
using a 40× water immersion objective and the FluoviewTM
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2.1 software. Image preparation and analysis was conducted
using Image J software as described above.
To ensure unbiased thresholding of the images when
comparing the different retinal regions or treatments, we
assigned a threshold value, using a custom written Image J
plugin, which determined the inflection point for the region
of interest (ROI) of each collapsed confocal optical image
stack. Briefly, on a plot of arbitrary fluorescent units obtained
from the confocal microscope versus the number of pixels in
the image, the inflection point was computed as a point on the
curve at which the tangent crossed the curve. Fluorescent
pixels above this threshold value were quantified for each ROI
using the “ROI manager.”
The quantitative analysis of these collapsed image stacks
was done using the freehand selection tool in Image J to select
specific ROIs. At least 25 ROIs from each animal in each
category and at least five animals in each treatment group were
analyzed in this manner. The average number of fluorescent
pixels of all images from one animal was considered as n=1.
The final graphs depict the mean and standard deviation (SD)
of at least n=5 animals to average out any minor local intensity
differences. The difference between the control and
experimental groups was analyzed using ANOVA. Post hoc
analysis was performed using Tukey’s test. A p<0.05 was
considered significant.
RESULTS
General condition of the mice used in this study: Mice with
STZID averaged a lower weight when compared to controls
after five weeks, however this difference was not statistically
significant (Table 1). The only statistically significant
differences were between control and insulin (p=0.0004) and
control and L-NAME (p=0.03). To our observation, the
diabetic mice had slightly diminished body appearance and
activity levels; their activity levels were returned to normal by
administering insulin or AG. In addition to diminished
bodyweight, the animals that received L-NAME appeared
more emaciated and lethargic than their untreated diabetic
counterparts (data not shown).
Blood glucose levels were significantly elevated in
diabetes (p<0.0001). These levels were significantly lowered
by insulin, although it was still significantly higher than
control (p<0.0001). L-NAME or AG did not appear to affect
blood glucose levels and were not significantly different from
untreated diabetic, but remained significantly different from
control and insulin treated animals (p<0.0001; Table 1).
NO increased after 5 weeks of STZID and was reduced by
insulin, aminoguanidine, or L-NAME: To examine any
changes in NO levels in the retina after 5 weeks of STZID, we
measured the NO-induced fluorescence (NO-IF) using the NO
sensitive dye DAF-FM. We detected basal levels of NO-IF in
all retinal layers in the dark-adapted retinas (Figure 1A). We
observed an overall increase in NO-IF in dark-adapted
diabetic retinas. In comparison to control retinas, the intensity
of NO-IF in diabetic retinas increased significantly in the outer
plexiform layer (OPL) by 82±19% (p<0.0001) and in the IPL
by 48±18% (p=0.016; Figure 1A,B). NO-IF also appeared in
the diabetic outer nuclear layer (ONL), which was usually not
seen in the control ONL (Figure 1A). Interestingly,
presumptive bipolar cells in the control inner nuclear layer
(INL) often had NO-IF both in their somata and processes, but
they appeared to have lost NO-IF in their processes in the
diabetic condition. There was no significant change in the
number or intensity of labeled cell bodies in the INL or
ganglion cell layer (GCL) in diabetic retinas when compared
to controls.
Treatment with insulin partially reduced the NO-IF in the
diabetic retinas (Figure 1A,B). Insulin treatment lowered NO-
IF levels in the OPL and IPL to about half that of the untreated
diabetics, however this trend was only statistically significant
in the OPL (p=0.01). Neither the number of cells exhibiting
NO-IF nor the intensity of NO-IF in the INL and GCL were
significantly different from controls. In addition, insulin
TABLE 1. HEALTH CHARACTERISTICS OF MICE USED IN THIS STUDY.
Experimental group Weight (g) Blood glucose (mg/dl)
Control 26±0.3 129±14
Diabetic 22±1 486±9
Insulin 17±2 264±14
L-NAME 21±1.8 454±23
AG 22±0.8 433±22
Mice with streptozotocin-induced diabetes (STZID) had lower weights when compared to controls after 5 weeks, but the
difference was not statistically significant. The differences in weight between control and insulin treatment (p=0.0004) and
control and Nω-nitro-L-arginine methyl ester (L-NAME; p=0.03) were significant. Blood glucose levels were significantly
elevated in diabetes (p<0.0001) and this was significantly lowered by insulin, although it was still significantly higher than
control (p<0.0001). L-NAME or aminoguanidine (AG) did not appear to affect blood glucose levels and were not significantly
different from untreated diabetic. Values are presented±SEM.
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restored NO-IF to some processes of somata in the INL and
greatly decreased the levels of NO-IF in the ONL (Figure 1A).
While insulin did help restore NO-IF to near normal levels,
we did not observe a complete rescue. This was most likely
because the insulin was only administered once daily. As a
consequence, the blood glucose levels of the insulin treated
mice were lower than the untreated diabetics, although their
blood glucose levels were still elevated above 250 mg/dl
(Table 1).
Treatment with L-NAME reduced retinal NO-IF to levels
too low to be detected by our NO imaging method (data not
shown). Treatment with AG significantly returned NO-IF to
near control levels in the OPL (86±14%, p<0.0001) and in the
IPL (80±18%, p=0.004; Figure 1B), but the NO-IF in the
processes in the INL did not return with AG treatment as it
Figure 1. Changes in NO-induced fluorescence (NO-IF) in the diabetic retina. A: NO-IF increased in the diabetic retina compared to control.
NO-IF in processes from somata in the inner nuclear layer (INL) were present in control (white arrowhead) but absent in the diabetic. Treatment
with insulin or aminoguanidine (AG) reduced NO-IF and insulin restored NO-IF in some the processes in the INL (white arrowheads). Scale
bars represent 25 μm. Quantitative analysis of NO-IF in retinal regions is shown in dark-adapted unstimulated (B) and light-stimulated retinas
(C) as compared to control (100%). The outer and inner plexiform layers (OPL and IPL) depict the percent intensity, while the inner nuclear
layer (INL) and ganglion cell layer (GCL) depict the percent of NO-IF labeled somata. B, C: Like symbols indicate statistically significant
differences between groups (* represents diabetic versus control OPL, # represents diabetes versus control IPL; p<0.05). Error bars represent
SD.
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did with insulin (Figure 1A). The number of cells exhibiting
NO-IF and intensity in the INL and GCL levels were not
significantly different from control.
While the results described were for dark-adapted,
unstimulated retinas, we also performed the same experiments
using retinas stimulated with flashing light (Figure 1C). The
results were comparable to retinas in the dark, although the
basal levels of NO-IF were higher in stimulated control
retinas. In diabetic mice, the NO-IF in the OPL significantly
increased by 49 ± 11% (p=0.0002), while in the IPL it went
up by 23±13% (p=0.02). Interestingly, insulin seemed to have
a stronger effect in the OPL and IPL of light-stimulated
retinas, significantly lowering NO-IF to near control levels in
the OPL (93±18%, p<0.0001) and in IPL (83±17%,
p=0.0016). AG had a dramatic effect in the light-stimulated
retinas, with intensities significantly down to 112±13% in the
OPL (p=0.02) and lower (but not statistically significant) to
98±14% in the IPL (Figure 1B,C).
nNOS protein levels decrease after 5 weeks of STZID: While
NO-IF increased, nNOS-like immunoreactivity (nNOS-LI)
significantly decreased by 21±11% in the OPL (p=0.005),
15±9% in the IPL (p=0.012), 19±17% in the INL (p=0.001),
and 26±14% in the GCL (p=0.006; Figure 2A). These changes
were not affected by treatment with insulin or AG (data not
shown). There was nNOS-LI in the IPL in many apparent
neuronal processes in control retinas. Interestingly, nNOS-LI
was largely absent from such processes of the IPL in the
diabetic condition and appeared more punctate in expression,
suggesting nNOS-LI was in synaptic boutons (Figure 2B).
Western blots probed with the nNOS antiserum confirmed an
overall reduction of nNOS protein by 24±11% (p=0.005),
consistent with our immunocytochemistry (ICC) findings
(Figure 2C).
To determine if the change in nNOS protein was due to
a decrease in nNOS gene expression, we performed qPCR
using an Applied Biosystem’s TaqMan™ assay. We found no
difference in nNOS mRNA expression levels between control
and diabetic retinas (Figure 3), an indication that changes in
nNOS protein levels were not due to changes in its gene
expression.
DISCUSSION
Neuronal versus vascular complications: Several studies of
DR find evidence for cellular and metabolic abnormalities in
retinal neurons before vascular complications [4,8,32]. In both
human and animal models of DR, retinal dysfunction can first
be detected using ERGs, long before any vascular pathology
becomes apparent [8]. However, permeability changes can
occur as early as eight days after diabetic onset in rats [33],
and future studies should consider this. Nonetheless, studies
that have looked at the vasculature in greater detail did not
find major vascular complications until 6 months to 21 months
after the onset of diabetes in rodents [11,32,34,35].
Role of nNOS in diabetic retinopathy: We found a large
increase in NO production, which mirrored the anatomic
localization of nNOS-LI, despite an overall decrease in nNOS
protein levels. There have been relatively few studies
examining nNOS in retinal neurons of diabetic animals, and
the results have varied. One study used a combination of
western blots and ICC to conclude that the number of nNOS-
positive bipolar cells increases in the INL of the diabetic rat
after nine weeks [26]. More consistent with our findings, an
Figure 2. nNOS protein levels decreased after 5 weeks of diabetes. A: Mean fluorescence levels of nNOS immunoreactivity were significantly
reduced in the outerplexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer (IPL), and ganglion cell layer (GCL) when
compared to controls (n=11). The graph on the right indicates the line profile average of the intensity of nNOS in each layer of the retina. B:
nNOS immunoreactivity in the IPL no longer filled neuronal processes in the diabetic and was localized in structures which resembled synaptic
boutons in size and location. C: western blots detected a single ~160 kDa band consistent with nNOS. Levels of β-tubulin are shown to confirm
equal protein loading. There was a 24%±11 decrease in total nNOS protein (C is control, D is diabetic; n=8). Line on the left indicates the
location of the 150 kDa molecular weight marker.
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earlier study using a combination of NADPH diaphorase
histochemistry and ICC found that the total number of nNOS
expressing neurons decreases, and this loss is prevented by
AG [27].
nNOS is responsible for the increases in NO-IF in the OPL
and IPL: It is theoretically possible that some of the NO-IF
we observed was produced from inducible NOS (iNOS) or
endothelial NOS (eNOS). Several studies have examined
iNOS as a potential mediator of DR. However, these studies
all indicated that iNOS plays a critical role in subsequent
vascular damage and do not link iNOS with early neuronal
dysfunction [36-38]. Du et al. [39], showed that high glucose
caused an increase in iNOS in the Müller cell culture line
rMC-1, but not in bovine retinal endothelial cells. Abu El-
Asrar et al. [38] detect iNOS in Müller cells of human patients
with DR, but not in any cells of the retinas of normal
individuals. Therefore, although iNOS is clearly involved in
the pathology of the diabetic retina, it is more closely
associated with glial and vascular complications. To our
knowledge, there is no definitive evidence linking iNOS to
the early neuronal pathology seen in DR, and there has been
no selective localization of iNOS within the IPL or OPL. In
contrast, our NO imaging results from this and previous
studies [24,25] clearly indicated that the NO-IF in retina is
closely anatomically correlated with nNOS-LI—observations
that support our belief that the increased NO was coming from
nNOS and not iNOS.
Although we detected relative low levels of eNOS mRNA
compared to nNOS mRNA in retina using qPCR and found
eNOS-LI in retinal vasculature (data not shown), we did not
detect eNOS in retinal neurons using several commercially
available eNOS antisera (Santa Cruz Biotechnology, Inc.,
sc8311, sc653, and sc654; BD Transduction Labs, 610298).
However, this was not surprising since previous work shows
only weak immunocytochemical staining of eNOS protein in
the INL and blood vessels, suggesting that it is not abundant
in the retina [36,40]. Although there is evidence that eNOS is
involved in vascular complications of DR, the vasculature
only makes up about 3%–5% of the retina [36,41]. Most
important, the increased NO-IF we observed in the plexiform
layers is not likely to be produced by eNOS, because the NO-
IF is clearly not associated with blood vessels.
If NO is contributing to various stages of DR, then it is
extremely important to find usable inhibitors of NOS as
potential therapeutic targets. Gross inhibition of NOS is not a
realistic option, as we found that L-NAME almost completely
eliminated NO-IF and this treatment was not well tolerated.
In the present study, AG was well tolerated, and it was
apparent that AG was able to inhibit nNOS. Other studies also
show that AG is not exclusively an iNOS inhibitor, as it is
often reported to be [42,43]. However, since AG is also an
inhibitor of AGE formation [44,45], we cannot discount the
role AGE formation may play in regulating NO levels.
Potential mechanisms for increased nNOS activity: In both
diabetic human [46] and rat retinas [47], there is increased
NMDA receptor NR1 subunit immunoreactivity. These
NMDA receptor channels provide an important route for
Ca2+ entry, and subsequent activation of Ca2+-dependent
intracellular enzymes such as nNOS. Neurotoxicity
associated with excitatory amino acids is reported to be
mediated to a large extent through the activation of NMDA
receptors [48]. Since nNOS activity is Ca2+-dependent and
calmodulin-dependent, it would be also be activated by these
Ca2+ increases [49]. Furthermore, a subset of nNOS resides at
the post-synaptic density by virtue of its PDZ-domain; this
may explain why the nNOS we find remaining in the diabetic
IPL appears largely synaptic [50]. Any nNOS at the post-
synaptic density would be in close proximity to the largest
influxes of calcium. Thus the reduction of nNOS protein may
be compensated for by large glutamate-induced influxes of
calcium at synapses.
Another significant possibility is that there is a post-
translational activation of nNOS. nNOS enzyme activity is
strongly inhibited by a Ca2+-dependent and calmodulin-
dependent protein kinase II that phosphorylates nNOS at
Figure 3. qPCR measurements of retinal nNOS transcripts using an
Applied Biosystems TaqMan™ assay. No difference was seen
between control and diabetic nNOS mRNA levels. The values are
depicted as mean normalized expression (MNE) compared to the 18s
rRNA (n=4). The data were analyzed using the qGene template
[30], using the following equation:
where; Etarget, PCR amplification efficiency of the target gene; Eref,
PCR amplification efficiency of the reference gene; CTtarget,
threshold cycle of the PCR amplification of the target gene; CTref,
threshold cycle of the PCR amplification of the reference gene. The
CT was defined as the cycle at which the fluorescence rises
appreciably above the background fluorescence and determined
automatically using Applied Biosystems SDS software version 2.3.
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MNE =
(Eref )
CTref , replicate1
(Etarget)
CTtarget , replicate1
+
(Eref )
CTref , replicate2
(Etarget)
CTtarget , replicate2
+
(Eref )
CTref , replicate3
(Etarget)
CTtarget , replicate3
+
(Eref )
CTref , replicate4
(Etarget)
CTtarget , replicate4
4
Ser847 [51,52]. Increased levels of Ca2+ can activate calcineurin
(PP2B) to dephosphorylate nNOS at Ser847, which in turn
allows nNOS to increase NO production [53]. Thus it is
possible that increased Ca2+ levels can stimulate NO
production in two distinct ways: by increasing intracellular
Ca2+ to directly activate nNOS, and by activating calcineurin
to activate nNOS through dephosphorylation of an inhibitory
site.
Consequences of increased NO production in diabetes: There
are several potential molecular and cellular consequences of
an increase in NO in synapses. One consequence of diabetes
is hypoxia in the diabetic retina [54]; NO from nNOS has been
shown to sensitize neurons to hypoxia-induced death via
competitive inhibition of cytochrome oxidase [55]. Thus, the
increased NO may contribute to the early neuronal cell death
in DR. NO has also been shown to increase release of
neurotransmitters through both cGMP-dependent
mechanisms [56] and through Ca2+ independent mechanisms
involving synaptic vesicle docking and fusion reactions [57].
In particular, NO has been shown to increase release of
glutamate in chick retina [58]. In contrast, NO has been shown
to decrease glycine release in retina [59]. Such increased
levels of retinal glutamate and decreased release of glycine
may also be related to the increased cell death in DR. These
neurochemical changes are consistent with studies using a
combination of ICC, western blots, and qPCR that report that
the presynaptic proteins synaptophysin, synapsin 1, VAMP2,
SNAP25, and PSD95 all showed decreases after only one
month of diabetes, especially when synaptosomal fractions
were selectively examined [18].
Future studies will need to determine the exact
mechanisms that led to the increase in nNOS activity. In
addition, it will be important to separate the timing and relative
contributions of nNOS versus iNOS to get an accurate picture
of how each pool of NO affects the retina as a whole. However,
the results of our study indicate that nNOS may play a major
role in providing excess NO in early DR. Future studies should
address how this pathologically increased NO can be
selectively reduced without detrimentally affecting the many
normal functions of NO in the retina. This approach could
provide a significant new strategy for treating the early
neuronal cell loss in DR.
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